Churg-Strauss syndrome with critical endomyocardial fibrosis: 10 year survival after combined surgical and medical management

C R McGavin, A J Marshall, C T Lewis

Heart 2002;87:e5 [http://www.heartjnl.com/cgi/content/full/87/5/e5]

CASE REPORT

A case is presented of the Churg-Strauss syndrome with hypereosinophilia and severe cardiac involvement, namely biventricular endomyocardial fibrosis and gross encroachment of the right ventricular cavity. The clinical picture was similar to Loeffler’s syndrome and the idiopathic hypereosinophilic syndrome. Combined aggressive surgical and medical management led to full recovery and survival at 10 years. The good long term outcome is attributed to strict control of peripheral eosinophil count by oral corticosteroids. This case illustrates the damaging effects of hypereosinophilia on the heart.

The Churg-Strauss syndrome is an inflammatory disease characterised by asthma and granulomatous angiitis together with tissue and blood eosinophilia. A prodromal phase has been described, with asthma and rhinitis, succeeded by an infiltrative eosinophilic phase with similarities to Loeffler’s syndrome, and finally a severe vasculitic phase. Cardiac complications have a major role in mortality and morbidity; endomyocardial fibrosis is described though rare. We present a patient with complete resolution of severe cardiac manifestations and prolonged survival after combined surgical and medical management.

CASE REPORT

A woman with a history of atopy and nasal polyposis developed asthma in 1985, aged 48 years. Symptoms were satisfactorily controlled for three years with inhaled salbutamol and beclomethasone, until a deterioration with pulmonary infiltrates and blood eosinophilia ($6 \times 10^9/l$). She required oral prednisolone at a variable dose over the next few years to control symptoms and the eosinophil count ranged between $0.6–4.8 \times 10^9/l$. In March 1991 the patient became systemically unwell with fever, weight loss, and malaise. The eosinophil count rose to a maximum of $12 \times 10^9/l$. She developed right heart failure, a left retinal infarct attributed to vasculitis, and bilateral foot drop with electrophysiological evidence of mononeuritis multiplex.

Renal function and serum IgE were normal. The echocardiogram (fig 1) showed gross encroachment into the right ventricular cavity by an echo dense mass and further, though less extensive, involvement of the left ventricle. Contractility was severely impaired and a pericardial effusion was present. Myocardial biopsy showed histological changes in keeping with endomyocardial fibrosis, with diffuse infiltration between myocytes of young connective tissue and some haemosiderin deposition.

Because of poor cardiac output the patient underwent open heart surgery. The right ventricle was opened and the cavity was found to be almost completely replaced by layers of well organised clot on the surface and yellow gelatinous fibrin about 3 mm thick over the myocardium, extending with a fairly clear line of demarcation from about 1 cm from the atrioventricular ring to about 1 cm of the pulmonary artery. The tricuspid chordae passed through the clot and the abnormal endocardial tissue adhered firmly to all the trabeculae. There was a plain between the muscle and the abnormal tissue but the tissue extended deeply into every crevice over the trabeculae. It was removed in numerous chippings very much like decorticating an empyema. By this means the bulk was substantially reduced. The tricuspid valve was replaced by a Carpentier Edwards xenograft. The left ventricle was not opened.
Postoperatively, she received corticosteroids, warfarin, azathioprine, aspirin, and dipyridamole. Progress was slow but the heart failure, visual impairment, and neuropathy resolved. It was possible to simplify the regimen to warfarin and prednisolone, the dose averaging about 5 mg daily and being adjusted carefully to maintain a normal blood eosinophil count. She has continued to require inhaled asthma medication. She remains in good health at 10 years after surgery and the echocardiogram is now normal (fig 2).

DISCUSSION

This patient fulfils the criteria for the Churg-Strauss syndrome despite a lack of histological evidence of angiitis. She also had hypereosinophilia by the definition of blood eosinophilia of $>1.5 \times 10^9/l$. The case is of note because of the severe encroachment of abnormal tissue into the cavity of the right ventricle, the description of the operative findings and procedure, and the excellent clinical outcome at 10 years. Of particular interest is the resolution of the left ventricular masses with immunosuppressive treatment alone. Although surgery was critical to the patient’s early survival, we attribute her good long term progress to meticulous control of the inflammatory process with oral steroids, using the blood eosinophil count as the marker of disease activity.

Cardiac involvement in Churg-Strauss syndrome is well described. Manifestations include coronary vasculitis, acute and constrictive pericarditis, myocardial fibrosis, and cardiac failure. Endomyocardial fibrosis similar to Loeffler’s syndrome as seen in this case has been recorded but is rare. This pattern of cardiac involvement has been more usually described in the idiopathic hypereosinophilic syndrome and the mechanisms by which eosinophilia may damage the heart are discussed by Spry. From their granules, eosinophils release proteins, including ribonucleases and eosinophil major basic protein, that attack parasites. These substances damage cardiac myocytes but not skeletal muscle.

Some authors consider that hypereosinophilic syndrome is a separate entity from Churg-Strauss syndrome, being defined as hypereosinophilia for more than six months in the absence of other recognised causes of hypereosinophilia. It seems more probable that there are overlap syndromes and that the cardiac damage is caused by the toxic effects of hypereosinophilia rather than by the underlying disease process. This leads to the conclusion that control of the blood eosinophil count in these syndromes is vital for cardiac health.

Authors’ affiliations

C R McGavin, A J Marshall, C T Lewis, Department of Respiratory Medicine, Derriford Hospital, Plymouth PL6 8DH, UK

Correspondence to: Dr McGavin, Departments of Respiratory Medicine, Cardiology, and Cardiac Surgery, Derriford Hospital, Plymouth PL6 8DH, UK; clive.mcgavin@phnt.swest.nhs.uk

Accepted 11 December 2001

REFERENCES


Churg-Strauss syndrome with critical endomyocardial fibrosis: 10 year survival after combined surgical and medical management
C R McGavin, A J Marshall and C T Lewis

*Heart* 2002 87: e5
doi: 10.1136/heart.87.5.e5

Updated information and services can be found at:
[http://heart.bmj.com/content/87/5/e5](http://heart.bmj.com/content/87/5/e5)

These include:

**References**
This article cites 4 articles, 2 of which you can access for free at:
[http://heart.bmj.com/content/87/5/e5#BIBL](http://heart.bmj.com/content/87/5/e5#BIBL)

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:
[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:
[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)